COST EFFECTIVENESS OF AN OUTCOME BASED REIMBURSEMENT MODEL OF PCSK9 INHIBITORS

被引：1
|
作者：
Oren, Ohad
Oren, Michal
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Tel Aviv Univ, Tel Aviv, Israel
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 71卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(18)32294-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A1753
引用
收藏
页码：1753 / 1753
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of PCSK9 Inhibitors Proof in the Modeling
    Bonow, Robert O.
    Harrington, Robert A.
    Yancy, Clyde W.
    JAMA CARDIOLOGY, 2017, 2 (12) : 1298 - 1299
  • [2] Cost-effectiveness evaluation of the use of PCSK9 inhibitors
    Civeira, Fernando
    Pedro-Botet, Juan
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2021, 68 (06): : 369 - 371
  • [3] Cost-effectiveness with PCSK9 inhibitors: a matter of costs
    Drexel, Heinz
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (01) : 23 - 24
  • [4] Are PCSK9 Inhibitors Cost Effective?
    Max J. Korman
    Kjetil Retterstøl
    Ivar Sønbø Kristiansen
    Torbjørn Wisløff
    PharmacoEconomics, 2018, 36 : 1031 - 1041
  • [5] Are PCSK9 Inhibitors Cost Effective?
    Korman, Max J.
    Retterstol, Kjetil
    Kristiansen, Ivar Sonbo
    Wisloff, Torbjorn
    PHARMACOECONOMICS, 2018, 36 (09) : 1031 - 1041
  • [6] The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
    Kumar, Radya
    Tonkin, Andrew
    Liew, Danny
    Zomer, Ella
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 267 : 183 - 187
  • [7] Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors
    Blumenthal, Daniel M.
    Goldman, Dana
    Jena, Anupam B.
    JAMA CARDIOLOGY, 2017, 2 (10) : 1063 - 1064
  • [8] Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
    Kazi, Dhruv S.
    Penko, Joanne
    Coxson, Pamela G.
    Moran, Andrew E.
    Ollendorf, Daniel A.
    Tice, Jeffrey A.
    Bibbins-Domingo, Kirsten
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (08): : 748 - 750
  • [9] PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
    Vicente-Valor, Juan
    Garcia-Gonzalez, Xandra
    Ibanez-Garcia, Sara
    Duran-Garcia, Maria Esther
    de Lorenzo-Pinto, Ana
    Rodriguez-Gonzalez, Carmen
    Mendez-Fernandez, Irene
    Percovich-Hualpa, Juan Carlos
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [10] PCSK9 inhibitors
    Farnier, Michel
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (03): : 66 - 70
12345